GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xcell Therapeutics Inc (XKRX:373110) » Definitions » EV-to-Revenue

Xcell Therapeutics (XKRX:373110) EV-to-Revenue : 20.87 (As of Jun. 04, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Xcell Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Xcell Therapeutics's enterprise value is ₩36,362 Mil. Xcell Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₩1,742 Mil. Therefore, Xcell Therapeutics's EV-to-Revenue for today is 20.87.

The historical rank and industry rank for Xcell Therapeutics's EV-to-Revenue or its related term are showing as below:

XKRX:373110' s EV-to-Revenue Range Over the Past 10 Years
Min: 17.9   Med: 24.22   Max: 45.62
Current: 20.87

During the past 6 years, the highest EV-to-Revenue of Xcell Therapeutics was 45.62. The lowest was 17.90. And the median was 24.22.

XKRX:373110's EV-to-Revenue is ranked worse than
69.28% of 996 companies
in the Biotechnology industry
Industry Median: 7.385 vs XKRX:373110: 20.87

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-04), Xcell Therapeutics's stock price is ₩3345.00. Xcell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ₩168.54. Therefore, Xcell Therapeutics's PS Ratio for today is 19.85.


Xcell Therapeutics EV-to-Revenue Historical Data

The historical data trend for Xcell Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcell Therapeutics EV-to-Revenue Chart

Xcell Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial - - - - 21.34

Xcell Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 43.01 21.34 22.53

Competitive Comparison of Xcell Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Xcell Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xcell Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xcell Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Xcell Therapeutics's EV-to-Revenue falls into.


;
;

Xcell Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Xcell Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=36362.333/1742.395
=20.87

Xcell Therapeutics's current Enterprise Value is ₩36,362 Mil.
Xcell Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,742 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcell Therapeutics  (XKRX:373110) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Xcell Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3345.00/168.54
=19.85

Xcell Therapeutics's share price for today is ₩3345.00.
Xcell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩168.54.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcell Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Xcell Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Xcell Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
333, Yeongdong-daero, Gangnam-gu, Seoul, KOR, 06188
Xcell Therapeutics Inc operates as a research company engaged in development of regenerative medicines. The company is developing proliferation media for various animal cell types.

Xcell Therapeutics Headlines

No Headlines